<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70448">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01825941</url>
  </required_header>
  <id_info>
    <org_study_id>HEDNET3</org_study_id>
    <nct_id>NCT01825941</nct_id>
  </id_info>
  <brief_title>Diphenhydramine for Acute Migraine</brief_title>
  <official_title>Diphenhydramine as Adjuvant Therapy for Acute Migraine. A Randomized Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parenteral diphenhydramine is commonly used as adjuvant therapy for acute migraine despite
      the fact that data supporting this practice do not exist. The investigators propose a
      randomized double blind study to test the hypothesis that 50mg of intravenous
      diphenhydramine, when added to standard migraine therapy, will result in a greater rate of
      sustained headache relief than standard migraine therapy alone. For this study, standard
      migraine therapy will be 10mg of intravenous metoclopramide. Sustained headache relief is
      defined as achieving a headache level of &quot;mild&quot; or &quot;none&quot; within two hours and maintaining a
      level of &quot;mild&quot; or &quot;none&quot; for 48 hours. Patients who present to the Montefiore emergency
      room (Bronx, NY) with an acute migraine will be approached for participation. They will be
      screened for medication contra-indications and non-migraine etiologies of headache. The
      study will be randomized. Assignment will be concealed. Participants and researchers will be
      blinded. Efficacy outcomes and adverse events will be assessed every half hour for two hours
      in the ED and by telephone 48 hours after medication administration. A sample size
      calculation, based on pilot data, revealed the need for 374 participants. An interim
      analysis will be performed after 200 participants have been enrolled with the goal of
      assessing for lack of conditional power.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained headache relief</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Obtaining a headache level = &quot;mild&quot; or &quot;none&quot; and maintaining a headache level = &quot;mild&quot; or &quot;none&quot; for 48 hours</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">374</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Metoclopramide + Diphenhydramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopramide + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Metoclopramide 10mg + placebo, administered intravenously over 15 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoclopramide</intervention_name>
    <description>10 milligrams, administered intravenously over 15 minutes</description>
    <arm_group_label>Metoclopramide + Diphenhydramine</arm_group_label>
    <arm_group_label>Metoclopramide + placebo</arm_group_label>
    <other_name>Reglan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diphenhydramine</intervention_name>
    <description>50 milligrams, administered intravenously over 15 minutes</description>
    <arm_group_label>Metoclopramide + Diphenhydramine</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Metoclopramide + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute migraine headache

          -  Present to our emergency room in the Bronx, NY for treatment of migraine headache

        Exclusion Criteria:

          -  Temperature &gt; 100.3 F

          -  Pheochromocytoma

          -  Seizure disorder

          -  Parkinson's disease

          -  Use of MAO inhibitors

          -  Use of anti-rejection transplant medications

          -  Use of potassium supplements

          -  Use of pramlintide
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Belinda Tavarez</last_name>
    <phone>718-920-8452</phone>
    <email>btavarez@montefiore.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belinda Tavarez</last_name>
      <phone>718-920-8452</phone>
      <email>btavarez@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin W Friedman, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin Friedman</investigator_full_name>
    <investigator_title>Associate professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>headache</keyword>
  <keyword>metoclopramide</keyword>
  <keyword>diphenhydramine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
